Flotek Industries (FTK) released its 4Q17 financial results on February 20. The company recorded operating revenues of $72.5 million in 4Q17, up 2.7% from the $70.6 million recorded in 4Q16.
In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) GeneSight reported revenues of $28.8 million, which is a YoY growth of 54% and a sequential growth of 12%.
Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.
On August 29, 2017, the FDA approved The Medicines Company’s (MDCO) Vabomere for treating adulating patients suffering with complicated urinary tract infections.
We’ll now look into Flotek Industries’ (FTK) segment performance in 2Q17. Revenues in the Energy Chemistry Technology (or ECT) segment rose 2% in 2Q17 over a year ago.
The Energy Chemistry Technology segment accounted for 76% of Flotek Industries’ revenues in 1Q17. The segment’s revenues rose 36% in 1Q17—compared to 1Q16.
Wholesale drives SuperValu’s top line As discussed, SuperValu (SVU) reported its 4Q17 results on April 25. The company returned to growth after several quarters of sales decline. The company’s wholesale segment was the key driver of its 1Q17 top line. Sales from this segment stood at $1.8 billion, up 3% YoY (year-over-year). Revenue growth was […]
We’ll now look into Flotek Industries’ (FTK) segment performance in 4Q16. The Energy Chemistry Technologies segment accounted for 68% FTK’s 4Q16 revenues.
In fiscal 3Q17, analysts expect $1.16 adjusted loss per share for Tidewater (TDW). Wall Street analysts expect Tidewater’s adjusted loss to deteriorate.
Since Tidewater’s fiscal 2Q17 financial results were announced on November 7, 2016, its implied volatility has decreased from 258% to the current level.
In fiscal 3Q17, analysts expect an ~$1.16 adjusted loss per share for Tidewater. Analysts expect Tidewater’s adjusted loss to fall in the coming quarter.
Flotek Industries’ operating cash flow In this article, we’ll analyze how Flotek Industries’ (FTK) operating cash flow has trended over the past few quarters. We’ll also discuss how its capital expenditure (capex) affected its free cash flow (or FCF). Flotek Industries’ cash from operating activities (or CFO) fell 62% between 3Q15 and 3Q16. FTK generated […]
FTK’s segment-wise income We discussed Flotek Industries’ (FTK) revenue in the previous part of this series. Operating income–wise, FTK’s Energy Chemistry Technologies segment fell 56.6% between 3Q15 and 3Q16. In contrast, its Consumer and Industrial Chemistry Technologies segment’s operating income rose ~41%. Between 3Q15 and 3Q16, Flotek Industries’ US revenue fell ~21%. Its revenue from […]
Flotek Industries’ revenue growth by segments Flotek Industries’ (FTK) Energy Chemistry Technologies segment accounted for 61% of FTK’s 3Q16 revenue. Revenue in this segment fell 25% between 3Q15 and 3Q16. Flotek Industries makes up 0.15% of the iShares S&P Small-Cap 600 Value ETF (IJS). The energy sector accounts for 4.3% of IJS. The Consumer and […]
